Adult Dosing
Contraception in females
- Recommended dose: 150 mg IM q3 months, administered by deep IM injection in the gluteal or deltoid muscle; max duration 2 yrs
- Recommended dose: 104 mg SC into the anterior thigh or abdomen q3 months (Depo-subQ provera)
Endometriosis (Depo-subQ provera)
- 104 mg SC into the anterior thigh or abdomen q3 months
Notes:- To ensure that the patient is not pregnant at the time of first injection, start during the first 5 days of a normal menstrual period
- The first injection should be given within the first 5-days postpartum if not breastfeeding; if breastfeeding, start only during or after the sixth postpartum week
Endometrial or renal carcinoma (Depo-Provera)
- Initial dose: 400-1000 mg/wk IM
- If improvement is observed within a few weeks or months, may maintain at 400 mg/month
Note: The suspension is intended for intramuscular administration only
Pediatric Dosing
- Safety and effectiveness in pediatric patients have not been established
[Outline]
- Medroxyprogesterone is associated with significant BMD loss; this loss seems to be greater with increased duration of use and may not be completely reversible. It is unknown whether therapy during adolescence or early adulthood, a critical period of bone accretion, will reduce peak bone mass and increase the risk for osteoporotic fracture in later life [US Black Box Warning]
- This can be used as long-term birth control method (>2 yrs) if other methods are inadequate [US Black Box Warning]
- Consider other birth control methods in the risk/benefit analysis when therapy is suggested in women with osteoporosis risk factors
- Disruption of menstrual bleeding patterns, manifested as amenorrhea, irregular/unpredictable/prolonged bleeding or spotting, and heavy bleeding, have occurred in women treated with medroxyprogesterone. If severe abnormal bleeding persists, rule out the possibility of organic pathology and institute appropriate treatment
- Serious thrombotic events have been reported in women using medroxyprogesterone. Physicians should remain alert if thrombotic disorders such as thrombophlebitis, pulmonary embolism, cerebrovascular disorders, and retinal thrombosis occur. If any of these events occur, do not re-administer the drug
- Because breast cancer may be hormonally sensitive, this drug should not be used in women who have or have had breast cancer
- Avoid re-administrating therapy if there is a sudden partial or complete loss of vision, sudden onset of proptosis, diplopia, migraine, papilledema or retinal vascular lesion
- Physician should remain alert to the possibility of an ectopic pregnancy among women using therapy who become pregnant or complain of severe abdominal pain
- Anaphylaxis and anaphylactoid reaction may occur with the use of this therapy. If an anaphylactic reaction occurs, appropriate therapy should be instituted with emergency medical treatment
- If jaundice or signs and symptoms of liver abnormality develop, discontinue the treatment and determine the cause. Do not resume use until markers of liver function return to normal; restart the treatment if liver abnormality is not related with therapy and liver function is acceptable
- Rare instances of convulsions have been reported in patients receiving medroxyprogesterone
- Evaluate blood pressure, breasts, abdomen and pelvic organs, including cervical cytology and relevant laboratory tests after initiation of medroxyprogesterone. If undiagnosed, persistent or recurrent abnormal vaginal bleeding occurs, appropriate measures should be conducted to rule out malignancy. Monitor women with a family history of breast cancer or who have breast nodules
- Women receiving medroxyprogesterone have reported fluid retention and weight changes
- Glucose intolerance has been reported in some patients receiving medroxyprogesterone; monitor diabetic patients while receiving therapy
- Return to fertility may likely be delayed after stopping this drug
- Medroxyprogesterone does not protect against HIV infection (AIDS) and other sexually transmitted diseases
- When multi-dose vials are used, special care should be taken to prevent contamination of the contents
Cautious: Use cautiously in
Pregnancy Category:X
Breastfeeding: Although non-hormonal methods are preferred during breastfeeding, progestin-only contraceptives such as depot medroxyprogesterone acetate (DMPA) are considered the hormonal contraceptives of choice during nursing. Evidence suggests that DMPA does not adversely affect the composition of milk, infant growth and development, or the milk supply. The product labeling indicates that it should not be started before 6 wks postpartum. Administration sooner than 3 days postpartum may inhibit lactogenesis and interfere with the establishment of lactation. It is prudent to administer this drug no sooner than 3 days postpartum when lactation is established. This information is based upon Lactmed database (available at http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT last accessed 15 April 2011). According to the manufacturer's data, no adverse events have been noted when used during lactation.
US Trade Name(s)
- Depo-Provera
- Depo-subQ provera 104
US Availability
medroxyprogesterone (generic)
- INJ: 150 mg/mL (1 mL vials)
- INJ: 150 mg/mL (1 mL prefilled syringes)
Depo-Provera
- INJ: 150 mg/mL (1 mL vials)
- INJ: 150 mg/mL (1 mL prefilled syringes)
- INJ: 400 mg/mL (2.5 mL vials)
Depo-subQ provera 104
- INJ (Prefilled syringes): 104 mg/0.65 mL
Canadian Trade Name(s)
- Depo-Provera
- Depo-Provera-SC
Canadian Availability
medroxyprogesterone (generic)
- INJ: 150 mg/mL (1 mL vials)
Depo-Provera
- INJ: 50 mg/mL ( 5 mL vials)
- INJ: 150 mg/mL (1 mL vials)
- INJ: 150 mg/mL (1 mL prefilled syringes)
Depo-Provera-SC
- INJ: 400 mg/mL (2.5 mL vials)
UK Trade Name(s)
UK Availability
Depo-Provera
- INJ: 150 mg/mL (1 mL vials)
- INJ: 150 mg/mL (1 mL prefilled syringes)
Australian Trade Name(s)
- Depo-Provera
- Depo-Ralovera
Australian Availability
Depo-Provera
- INJ: 150 mg/mL (1 mL vials)
Depo-Ralovera
- INJ: 150 mg/mL (1 mL vials)
[Outline]
Pricing data from www.DrugStore.com in U.S.A.
- Depo-Provera 150 MG/ML SUSP [Syringe] (PFIZER U.S.)
1 ml = $100.78
3 ml = $268.74 - Depo-Provera 400 MG/ML SUSP [Vial] (PFIZER U.S.)
2.5 ml = $191.59
7.5 ml = $541.99
Warning: This pricing information is subject to change at the sole discretion of DS Pharmacy. For the most current and up-to-date pricing information, please visit drugstore.com.